Genetic medicines company nChroma Bio has received a Certificate for Clinical Trial in Hong Kong to start the Phase I/II trial of its treatment for chronic hepatitis B virus (HBV). 

CRMA-1001 is an optimised next-generation epigenetic silencer, designed to durably silence HBV antigen expression by methylating both covalently closed circular DNA (cccDNA) and integrated HBV DNA (intDNA) without cutting or nicking the genome. This innovative strategy could provide a functional cure for millions of people living with HBV. 

It is estimated that over 250 million people worldwide are living with HBV, meaning there is a significant unmet need to develop life-long, finite-course curative treatments. 

 “This regulatory clearance marks a defining milestone for nChroma and for patients affected by chronic HBV,” said Jeff Walsh, Chief Executive Officer of nChroma Bio.  

“We see a real opportunity to change the trajectory of chronic hepatitis B by delivering deeper, more sustained responses driven by potentially best-in-class potency, going beyond the limits of existing and investigational treatments.” 

Professor Man-Fung Yuen, an internationally recognised researcher in the field of hepatitis B and Chair Professor at The University of Hong, will lead the study.  

“Hepatitis B remains a major global public health challenge that can lead to life-threatening conditions such as cirrhosis and liver cancer,” said Yuen.  

“I am honoured to serve as a Principal Investigator for the Phase I/II clinical trial of CRMA-1001 here in Hong Kong.  

“As a novel epigenetic silencer, I am enthusiastic about the promising potential of CRMA-1001 to achieve functional cure for persons living with HBV and I look forward to contributing to the development effort that could change the future for millions of people worldwide.” 

 

Bruno Quinney, Content Team, DDW